SOLAR Eclipsed As Astellas Drops EGFR Inhibitor On Late-Stage Failure
Executive Summary
Another casualty in the third-generation EGFR inhibitor category leaves Astellas with a hole in its non-small cell cancer pipeline as Tarceva heads towards patent expiry.